Skip to search formSkip to main contentSkip to account menu

ECOG performance status

Known as: ECOG Score, ECOG1-Performance Status, ECOG101 
A performance status scale designed to assess disease progression and its affect on the daily living abilities of the patient.
National Institutes of Health

Related topics

Related topics

3 relations
CDISC Questionnaire ECOG Test Code TerminologyClinical Data Interchange Standards Consortium TerminologyZubrod Performance Status

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
EXTENDED FOLLOW‐UP OF A PHASE I TRIAL OF IPILIMUMAB, NIVOLUMAB AND BRENTUXIMAB VEDOTIN IN RELAPSED HODGKIN LYMPHOMA: A TRIAL OF THE ECOG‐ACRIN RESEARCH GROUP (E4412)
phoma (Frank, Cancer Discov, 2018). Ibrutinib compromises B-cell survival by inhibiting Bruton’s tyrosine kinase, but also… 
2019
2019
Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin‐2 use in solid tumors: A feasibility off‐label experience
Review
2018
Review
2018
Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation
Background Neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR) and modified Glasgow prognostic score (mGPS… 
2017
2017
KEYNOTE-010: flash of a supernova (immune-checkpoint inhibitors) in second-line non-small cell lung cancer.
The KEYNOTE 021 trial was a randomized phase II/III trial comparing docetaxel and pembrolizumab as a secondline treatment for non… 
2015
2015
Risk of acute myocardial infarction after androgen‐deprivation therapy for prostate cancer in a Chinese population
To investigate the risk of acute myocardial infarction (AMI) after androgen‐deprivation therapy (ADT) for prostate cancer in a… 
2015
2015
Tolerability and outcomes of curative radiotherapy in patients aged 85 or more years
Objectives: To assess the tolerability and survival outcome of curative radiotherapy in patients over the age of 85 years. 
2014
2014
Identification of Subsets of Patients with Favorable Prognosis After Recurrence in Completely Resected Non-Small Cell Lung Cancer
AbstractBackgroundThis retrospective study aimed to determine prognostic factors associated with postrecurrence survival of… 
2013
2013
Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
2011
2011
A randomized phase II study of pemetrexed versus pemetrexed plus erlotinib in second-line treatment for locally advanced or metastatic, nonsquamous NSCLC.
7526 Background: PEM and ERL have been approved as second-line monotherapy for locally advanced or metastatic NSCLC. The… 
2004
2004
Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil
We have recently demonstrated that continuous-infusion (CI) 5-fluororacil (FU) eradicates human colon carcinoma cells made… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)